Stereotactic biopsy suit heats up

Article

Lorad Medical Systems and Fischer Imaging wielded charges andcountercharges last week during pretrial procedures for Fischer'sstereotactic-guided biopsy patent infringement suit (SCAN 4/8/92). Lorad fired the first public shot with release of a

Lorad Medical Systems and Fischer Imaging wielded charges andcountercharges last week during pretrial procedures for Fischer'sstereotactic-guided biopsy patent infringement suit (SCAN 4/8/92).

Lorad fired the first public shot with release of a statementthat Fischer Imaging has dropped two more of its patent claimsfiled against Lorad. Only two claims remain, down from the 16originally filed in April, Lorad said.

Withdrawing its patent claims one at a time is a way of droppingthe suit while saving face, according to Lorad.

"It's only a matter of time before this case is dismissed,"said Hal Kirshner, Lorad president.

Fischer countered with its own public statement discountingthe importance of the reduced number of claims. Narrowing thenumber of claims is common practice in patent suits as informationis reviewed during the discovery period, said Robert A. Cascella,executive vice president and CFO of Fischer.

Fischer initially cited five interrelated claims against Loradin its suit and reduced this to the two primary claims after reviewingLorad technical documentation, he said. These two claims, regardingelements of prone positioning, the stereotactic guided arm anddigital processing, had always been the essence of the patents,he said.

Lorad has made other claims about Fischer's image quality thatare not substantiated by comparative testing of the two systems,according to the Fischer statement. The company is consideringadditional nonpatent litigation against Lorad related to theseproduct claims, the company said.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.